Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of VG290131 in Healthy Adults
NCT06081465Phase 1Recruiting
- Sponsor
- Zhejiang Vimgreen Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VG-290131 in Nonalcoholic steatohepatitis (NASH) (10 cohorts), sponsored by Zhejiang Vimgreen Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events up to 12 days, 12-Lead Electrocardiogram up to 12 days and 3 more. Started Oct 2023; status: recruiting.
02
Drugs
VG-290131
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06081465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081465.